Therapie der okulären Graft-versus-Host-Erkrankung

Abstract

Therapy for ocular graft-vs-host disease (ocular GvHD) is challenging for ophthalmologists as progress of the disease often occurs rapidly and is unforeseeable. Primary goal is the preservation or restoration of visual acuity, however, studies on ocular GvHD that have investigated therapeutic concepts are limited. In contrast, most therapeutic recommendations from consensus conferences derive from studies on dry eye diseases other than ocular GvHD. This review demonstrates the available therapies in the following categories: local, systemic, surgical and prophylactic. Primary targets are anti-inflammation, anti-fibrosis and lubrification of the ocular surface. In conclusion, studies strictly on ocular GvHD are needed to enable better evidence-based therapeutic decision-making in the future.

Evidence For Dry Eye Treatment In Hematopoietic Stem Cells Post-Transplantation

“…The beneficial effect of corticosteroids reported on the findings [33] corroborates those described in other studies, the use of which is recommended especially when there is a proliferation of signs of inflammation [55].…”

A szaruhártya immunológiai betegségei (Pontszerző, referáló közlemény, tesztkérdésekkel)

“…Emellett megtalálhatók szaruhártya-eróziók, -fekélyek (5. ábra), scleritis, episcleritis, anterior és posterior uveitis. Kezelésében a lokális műkönny rendszeres használata és lokális szteroidos cseppek (legfeljebb 3× naponta) elengedhetetlenek (20,21,22).…”